Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (82)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Milasin, J.
Right arrow Articles by Giacca, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milasin, J.
Right arrow Articles by Giacca, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 5, 73-79, Copyright © 1996 by Oxford University Press

ARTICLES

A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy

J Milasin, F Muntoni, GM Severini, L Bartoloni, M Vatta, M Krajinovic, A Mateddu, C Angelini, F Camerini, A Falaschi, L Mestroni and M Giacca
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.

X-linked dilated cardiomyopathy (XLDC) is a familial heart disease presenting in young males as a rapidly progressive congestive heart failure, without clinical signs of skeletal myopathy. This condition has recently been linked to the dystrophin gene in some families and deletions encompassing the genomic region coding for the first muscle exon have been detected. In order to identify the defect responsible for this disease at the molecular level and to understand the reasons for the selective heart involvement, a family with a severe form of XLDC was studied. In the affected members, no deletions of the dystrophin gene were observed. Analysis of the muscle promoter, first exon and intron regions revealed the presence of a single point mutation at the first exon-intron boundary, inactivating the universally conserved 5' splice site consensus sequence of the first intron. This mutation introduced a new restriction site for MseI, which cosegregates with the disease in the analyzed family. Expression of the major dystrophin mRNA isoforms (from the muscle-, brain- and Purkinje cell-promoters) was completely abolished in the myocardium, while the brain- and Purkinje cell- (but not the muscle-) isoforms were detectable in the skeletal muscle. Immunocytochemical studies with anti- dystrophin antibodies showed that the protein was reduced in quantity but normally distributed in the skeletal muscle, while it was undetectable in the cardiac muscle. These findings indicate that expression of the muscle dystrophin isoform is critical for myocardial function and suggest that selective heart involvement in dystrophin- linked dilated cardiomyopathy is related to the absence, in the heart, of a compensatory expression of dystrophin from alternative promoters.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger
Designing Heart Performance by Gene Transfer
Physiol Rev, October 1, 2008; 88(4): 1567 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 J HeredHome page
U. Philipp, C. Broschk, A. Vollmar, and O. Distl
Evaluation of Tafazzin as Candidate for Dilated Cardiomyopathy in Irish Wolfhounds
J. Hered., July 9, 2007; (2007) esm045v1.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
S. Kimura, M. Ikezawa, S. Ozasa, K. Ito, H. Ueno, K. Yoshioka, S. Ijiri, K. Nomura, K. Nakamura, M. Matuskura, et al.
Novel Mutation in Splicing Donor of Dystrophin Gene First Exon in a Patient With Dilated Cardiomyopathy but No Clinical Signs of Skeletal Myopathy
J Child Neurol, July 1, 2007; 22(7): 901 - 906.
[Abstract] [PDF]

Home page
 Hum Mol GenetHome page
D. Duan
Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R253 - R261.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Section on Cardiology and Cardiac Surgery
Cardiovascular Health Supervision for Individuals Affected by Duchenne or Becker Muscular Dystrophy
Pediatrics, December 1, 2005; 116(6): 1569 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
T. W. Prior and S. J. Bridgeman
Experience and Strategy for the Molecular Testing of Duchenne Muscular Dystrophy
J. Mol. Diagn., August 1, 2005; 7(3): 317 - 326.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. L. Burkett and R. E. Hershberger
Clinical and genetic issues in familial dilated cardiomyopathy
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 969 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
Y. De Repentigny, P. Marshall, R. G. Worton, and R. Kothary
The mouse dystrophin muscle enhancer-1 imparts skeletal muscle, but not cardiac muscle, expression onto the dystrophin Purkinje promoter in transgenic mice
Hum. Mol. Genet., November 15, 2004; 13(22): 2853 - 2862.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Katsuragi, R. Morishita, N. Nakamura, T. Ochiai, Y. Taniyama, Y. Hasegawa, K. Kawashima, Y. Kaneda, T. Ogihara, and K. Sugimura
Periostin as a Novel Factor Responsible for Ventricular Dilation
Circulation, September 28, 2004; 110(13): 1806 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N Cohen and F Muntoni
Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy
Heart, August 1, 2004; 90(8): 835 - 841.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
K. A. Lapidos, R. Kakkar, and E. M. McNally
The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma
Circ. Res., April 30, 2004; 94(8): 1023 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. R. G. Taylor, P. R. Fain, G. Sinagra, M. L. Robinson, A. D. Robertson, E. Carniel, A. Di Lenarda, T. J. Bohlmeyer, D. A. Ferguson, G. L. Brodsky, et al.
Natural history of dilated cardiomyopathy due to lamin A/C gene mutations
J. Am. Coll. Cardiol., March 5, 2003; 41(5): 771 - 780.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Feng, J. Yan, C. H. Buzin, S. S. Sommer, and J. A. Towbin
Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy
J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1120 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Bastianutto, J. A. Bestard, K. Lahnakoski, D. Broere, M. De Visser, M. Zaccolo, T. Pozzan, A. Ferlini, F. Muntoni, T. Patarnello, et al.
Dystrophin muscle enhancer 1 is implicated in the activation of non-muscle isoforms in the skeletal muscle of patients with X-linked dilated cardiomyopathy
Hum. Mol. Genet., November 1, 2001; 10(23): 2627 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Su, A. Yao, I. Zubair, K. Sugishita, M. Ritter, F. Li, J. J. Hunter, K. R. Chien, and W. H. Barry
Effects of deletion of muscle LIM protein on myocyte function
Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2665 - H2673.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
E. Arbustini, P. Morbini, A. Pilotto, A. Gavazzi, and L. Tavazzi
Familial dilated cardiomyopathy: from clinical presentation to molecular genetics
Eur. Heart J., November 2, 2000; 21(22): 1825 - 1832.
[PDF]

Home page
 Hum Mol GenetHome page
E. E. Norgett, S. J. Hatsell, L. Carvajal-Huerta, J.-C. Ruiz Cabezas, J. Common, P. E. Purkis, N. Whittock, I. M. Leigh, H. P. Stevens, and D. P. Kelsell
Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma
Hum. Mol. Genet., November 1, 2000; 9(18): 2761 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Arbustini, M. Diegoli, P. Morbini, B. Dal Bello, N. Banchieri, A. Pilotto, F. Magani, M. Grasso, J. Narula, A. Gavazzi, et al.
Prevalence and characteristics of dystrophin defects in adult male patients with dilated cardiomyopathy
J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1760 - 1768.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. S. Lader, D. J. Kwiatkowski, and H. F. Cantiello
Role of gelsolin in the actin filament regulation of cardiac L-type calcium channels
Am J Physiol Cell Physiol, December 1, 1999; 277(6): C1277 - C1283.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. Mestroni, C. Rocco, D. Gregori, G. Sinagra, A. Di Lenarda, S. Miocic, M. Vatta, B. Pinamonti, F. Muntoni, A. L. P. Caforio, et al.
Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity
J. Am. Coll. Cardiol., July 1, 1999; 34(1): 181 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. Komajda, P. Charron, and F. Tesson
Genetic aspects of heart failure
Eur J Heart Fail, June 1, 1999; 1(2): 121 - 126.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. G. Priori, J. Barhanin, R. N. W. Hauer, W. Haverkamp, H. J. Jongsma, A. G. Kleber, W. J. McKenna, D. M. Roden, Y. Rudy, K. Schwartz, et al.
Genetic and Molecular Basis of Cardiac Arrhythmias: Impact on Clinical Management Parts I and II
Circulation, February 2, 1999; 99(4): 518 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
S.G. Priori, J. Barhanin, R.N.W. Hauer, W. Haverkamp, H.J. Jongsma, A.G. Kleber, W.J. McKenna, D.M. Roden, Y. Rudy, K. Schwartz, et al.
Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management
Eur. Heart J., February 1, 1999; 20(3): 174 - 195.
[PDF]

Home page
 HeartHome page
F. Muntoni, A. Di Lenarda, M. Porcu, G. Sinagra, A. Mateddu, G. Marrosu, A. Ferlini, M. Cau, J. Milasin, M. A. Melis, et al.
Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy
Heart, December 1, 1997; 78(6): 608 - 612.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. H. Beggs
Dystrophinopathy, The Expanding Phenotype: Dystrophin Abnormalities in X-Linked Dilated Cardiomyopathy
Circulation, May 20, 1997; 95(10): 2344 - 2347.
[Full Text]

Home page
 CirculationHome page
R. Ortiz-Lopez, H. Li, J. Su, V. Goytia, and J. A. Towbin
Evidence for a Dystrophin Missense Mutation as a Cause of X-Linked Dilated Cardiomyopathy
Circulation, May 20, 1997; 95(10): 2434 - 2440.
[Abstract] [Full Text]

Home page
 CirculationHome page
P. Melacini, M. Fanin, G.A. Danieli, C. Villanova, F. Martinello, M. Miorin, M.P. Freda, M. Miorelli, M.L. Mostacciuolo, G. Fasoli, et al.
Myocardial Involvement Is Very Frequent Among Patients Affected With Subclinical Becker's Muscular Dystrophy
Circulation, December 15, 1996; 94(12): 3168 - 3175.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
P. Marshall, N. Chartrand, and R. G. Worton
The Mouse Dystrophin Enhancer Is Regulated by MyoD, E-box-binding Factors, and by the Serum Response Factor
J. Biol. Chem., June 1, 2001; 276(23): 20719 - 20726.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.